Stage 1 Prostate Cancer Treatment: Complete Guide
Stage 1 prostate cancer is early-stage disease confined to the prostate gland. With nearly 100% five-year survival rate, stage 1 offers excellent outcomes. Many men choose active surveillance over immediate treatment, avoiding side effects while maintaining safety.
What Is Stage 1 Prostate Cancer?
Stage 1 prostate cancer means the tumor is small, localized entirely within the prostate gland, and hasn't spread beyond it. The cancer is typically non-palpable during digital rectal exam and discovered through PSA screening.
Characteristics:
- •PSA levelUsually <10 ng/mL
- •Gleason scoreTypically 6 or less (Grade Group 1)
- •Tumor extentOften affecting ≤50% of biopsy cores
- •No spreadConfined to prostate, no lymph node or distant involvement
About 80-85% of prostate cancers are diagnosed at stages 1, 2, or 3 (localized/regional disease).
Symptoms and Signs
Stage 1 prostate cancer typically causes no symptoms. Most men are diagnosed through routine PSA screening while feeling completely healthy.
When symptoms do occur, they're usually mild urinary changes:
- •Slightly more frequent urination
- •Weak urinary stream
- •Difficulty starting urination
These symptoms often relate to benign prostate enlargement rather than cancer itself.
Causes and Risk Factors
- •AgeRisk rises after 50; most diagnoses occur in men over 65.
- •Family historyHaving a first-degree relative with prostate cancer doubles risk.
- •Genetic mutationsBRCA1, BRCA2, Lynch syndrome increase risk.
- •RaceMen of African descent have higher incidence.
- •PSA screeningEnables early detection of stage 1 disease before symptoms appear.
Diagnosis and Staging
- •PSA testshows mildly elevated levels (typically <10 ng/mL).
- •Digital Rectal Examoften cannot detect stage 1 tumors—they're too small.
- •Biopsyconfirms cancer and assigns Gleason score. Stage 1 typically shows Gleason 6 (Grade Group 1).
- •Imaging (MRI, if performed)confirms cancer is contained within prostate.
- •Confirmatory biopsywithin 6 months is recommended for men considering active surveillance to verify low-risk classification.
Treatment Options for Stage 1 Prostate Cancer
Active Surveillance (Preferred Approach)
Active surveillance is now the preferred approach for stage 1 prostate cancer. About 60% of US men with low-risk disease choose active surveillance, up from 26.5% in 2014.
What it involves:
- •PSA testsevery 3-6 months
- •Digital Rectal Examevery 6-12 months
- •Repeat biopsiesevery 1-3 years
- •MRI imagingincreasingly used for monitoring
Goal: Monitor cancer closely with curative treatment if progression occurs.
Who qualifies: Men with low-risk features (Gleason 6, PSA <10, limited biopsy involvement) and life expectancy >10 years.
Outcomes: Studies show active surveillance doesn't increase prostate cancer death risk compared to immediate treatment. 10-year prostate cancer-specific survival exceeds 97%, with treatment-free probability of 64% at 10 years and 58% at 15 years.
When treatment starts: If repeat biopsies show Gleason 7 or higher, increasing tumor volume, or PSA rises significantly.
Watchful Waiting

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.
Watchful waiting differs from active surveillance—it's less intensive monitoring with treatment only if symptoms develop.
Who it's for: Older men (>75) with limited life expectancy or significant health problems making curative treatment unsafe.
Approach: Annual PSA tests, symptom monitoring. Palliative treatment (hormone therapy) if symptoms develop.
Radical Prostatectomy (Surgery)
Radical prostatectomy removes the entire prostate. For stage 1, surgery achieves nearly 100% cure rate.
Side effects: Urinary incontinence (improving over 6-12 months), erectile dysfunction (30-70%), bladder neck contracture (5-10%).
When considered: Men choosing immediate treatment, younger men wanting definitive cure.
Radiation Therapy
External beam radiation (EBRT) or brachytherapy (radioactive seed implants) achieve cure rates similar to surgery—nearly 100% for stage 1.
Side effects: Urinary frequency, bowel changes, gradual erectile dysfunction (30-50% over 2-3 years).
When considered: Men choosing immediate treatment who prefer non-invasive approach.
Focal Therapy
Focal therapies (cryotherapy, HIFU) target only cancer-containing areas, sparing healthy tissue. Fewer side effects but less long-term data. Available at specialized centers.
Prognosis and Survival Rates
- •Five-year survivalNearly 100%
- •Ten-year survival98%
Stage 1 is highly curable. Most men live normal lifespans.
Active Surveillance Safety
- •Prostate cancer-specific survival97-99% at 10-15 years
- •Metastasis risk0.4-2.8% at 15 years
- •Treatment conversion30-40% eventually receive treatment with excellent outcomes
Men on surveillance who later need treatment have similar cure rates to those treated immediately.
Why Choose Everhope for Stage 1 Prostate Cancer Care
Everhope's stage 1 program emphasizes personalized decision-making. We provide comprehensive active surveillance with MRI-guided monitoring, PSA tracking, and advanced biopsy techniques.
Our multidisciplinary team helps you understand surveillance versus treatment options, respecting your preferences. For men choosing treatment, we offer expert surgery and state-of-the-art radiation therapy.
FAQs
Yes, stage 1 is highly curable with nearly 100% five-year survival. Treatment options (surgery, radiation) achieve excellent cure rates. Active surveillance is also safe, allowing treatment if cancer progresses.
For low-risk stage 1 disease, active surveillance is now preferred by most guidelines. Studies show it doesn't increase death risk while avoiding treatment side effects. However, some men prefer immediate treatment for peace of mind. Discuss with your oncologist based on your cancer characteristics, age, and preferences.
Risk is very low. Studies show 0.4-2.8% metastasis risk at 15 years with proper surveillance. Regular monitoring catches progression early, allowing curative treatment before spread occurs.
Active surveillance involves intensive monitoring (PSA every 3-6 months, regular biopsies) with curative treatment if cancer progresses. It's for men with >10 years life expectancy. Watchful waiting is less intensive monitoring with palliative treatment only if symptoms develop—for older men or those with limited life expectancy.
Surgery risks include urinary incontinence (improving over months) and erectile dysfunction (30-70%). Radiation causes urinary frequency, bowel changes, and gradual erectile dysfunction (30-50% over 2-3 years). Active surveillance avoids these side effects initially, with 60%+ never needing treatment.
Typically every 1-3 years, with confirmatory biopsy within 6 months of diagnosis. MRI increasingly reduces biopsy frequency by identifying concerning changes. Many programs now use MRI-targeted biopsies for better accuracy.
Absolutely. About 30-40% of men on active surveillance eventually choose treatment, typically due to Gleason grade progression or increasing tumor volume. Outcomes remain excellent—delayed treatment doesn't reduce cure rates for low-risk disease.
Table of Content
- What Is Stage 1 Prostate Cancer?
- Characteristics:
- Symptoms and Signs
- Causes and Risk Factors
- Diagnosis and Staging
- Treatment Options for Stage 1 Prostate Cancer
- Active Surveillance (Preferred Approach)
- What it involves:
- Watchful Waiting
- Radical Prostatectomy (Surgery)
- Radiation Therapy
- Focal Therapy
- Prognosis and Survival Rates
- Active Surveillance Safety
- Why Choose Everhope for Stage 1 Prostate Cancer Care
